Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10007881 | 0.85 | HDAC1 (0.39) | PIK3CDPIK3R1 | |
| SCHEMBL18123307 | 0.85 | PIK3CD (0.44) | PIK3CDL3MBTL3L3MBTL1EPHX2PIK3CG | |
| SCHEMBL18123517 | 0.83 | PIK3CD (0.46) | PIK3CDL3MBTL3L3MBTL1 | |
| SCHEMBL9937580 | 0.83 | HDAC1 (0.42) | PIK3CD | |
| SCHEMBL18123512 | 0.83 | PIK3CD (0.68) | PIK3CDHRH3L3MBTL3L3MBTL1PIK3R1 | |
| SCHEMBL12268013 | 0.82 | HDAC1 (0.39) | PIK3CD | |
| SCHEMBL21523566 | 0.82 | HDAC1 (0.38) | PIK3CDHRH3 | |
| SCHEMBL18123513 | 0.82 | PIK3CD (0.54) | PIK3CDHRH3L3MBTL3L3MBTL1PIK3R1 | |
| SCHEMBL9937201 | 0.82 | HDAC1 (0.36) | PIK3CDHRH3 | |
| SCHEMBL18114714 | 0.80 | P2RY12 (0.38) | PIK3CDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822336-B2 | Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-03 | — | — | US | disclosed |
| US-10822336-B2 | Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-03 | — | — | US | disclosed |
| EP-3521290-A1 | CRYSTALS OF [2-(1-METHYL-1H-PYRAZOL-4-YL)-6-(MORPHOLIN-4-YL)-9H-PURIN-8-YL][4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]METHANONE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521290-A1 | CRYSTALS OF [2-(1-METHYL-1H-PYRAZOL-4-YL)-6-(MORPHOLIN-4-YL)-9H-PURIN-8-YL][4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]METHANONE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20190225614-A1 | CRYSTALS OF [2-(1-METHYL-1H-PYRAZOL-4-YL)-6(MORPHOLIN-4-YL)-9H-PURIN-8-YL][4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]METHANONE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190225614-A1 | CRYSTALS OF [2-(1-METHYL-1H-PYRAZOL-4-YL)-6(MORPHOLIN-4-YL)-9H-PURIN-8-YL][4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]METHANONE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| WO-2018062382-A1 | CRYSTALS OF [2-(1-METHYL-1H-PYRAZOL-4-YL)-6-(MORPHOLIN-4-YL)-9H-PURIN-8-YL][4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]METHANONE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 第一三共株式会社 | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225614-A1 | CRYSTALS OF [2-(1-METHYL-1H-PYRAZOL-4-YL)-6(MORPHOLIN-4-YL)-9H-PURIN-8-YL][4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]METHANONE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CMPK1, SYMPK, MCOLN2 | PIK3CD 2867/4885HRH3 2219/4885L3MBTL3 4636/4885 |
| US-10822336-B2 | Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof | CMPK1, SYMPK, MCOLN2 | PIK3CD 2867/4885HRH3 2219/4885L3MBTL3 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.